Skip to main content
Erschienen in: Spektrum der Augenheilkunde 5/2013

01.10.2013 | original article

The incidence and treatment of diabetic macular edema at the University Eye-Clinic Graz for a period of 2 years

verfasst von: Dr Monja Michelitsch, Priv-Doz Dr Vanessa Gasser-Steiner, Univ -Prof Dr phil Peter Gasser-Steiner

Erschienen in: Spektrum der Augenheilkunde | Ausgabe 5/2013

Einloggen, um Zugang zu erhalten

Summary

Background

A leading cause for permanent vision loss in diabetic patients with diabetic retinopathy is the occurrence of diabetic macular edema. New treatments, antivascular endothelial growth factors, for diabetic macular edema (DME) have been under trial and found to improve visual acuity more effective than the standard care treatment, central photocoagulation. The purpose of the following study was to estimate the future number of visiting DME patients and their treatment demands at the University Eye-Clinic Graz.

Material and methods

A retrospective 2-year-analysis was performed on all eyes of patients with initial occurrence of diabetic macular edema, visiting the University Eye Clinic Graz between 1 July 2009 and 31 June 2011. Main outcome was to establish a 2-year-incidence for DME at the University Eye Clinic Graz. Further assessments were the distribution of treatments received and the number of intravitreal medication applied.

Results

The incidence rate for the first year period was 105 persons and for the second year period 101 persons. Of the 226 treated eyes, 40.1 % received “laser treatment plus bevacizumab injections”, 25.2 % “laser treatment”, 21.1 % “bevacizumab injections” and 13.2 % “additional triamcinolone acetonide injections”. During the 2 years a total number of 343 intravitreal injections were administered, of which 293 were bevacizumab injections with the majority of bevacizumab treated eyes receiving 1–2 injections.

Conclusions

There seems to be a seasonal influence increasing the development of diabetic macular edema. The high treatment demands of DME with foveal involvement have made antivascular endothelial growth factors essential in the treatment of diabetic macular edema.
Literatur
1.
Zurück zum Zitat Resnikoff S, Pascolini D, Etya’ale D, et al. Global data on visual impairment in the year 2002. Bull World Health Organ. 2004;82:844–51.PubMed Resnikoff S, Pascolini D, Etya’ale D, et al. Global data on visual impairment in the year 2002. Bull World Health Organ. 2004;82:844–51.PubMed
2.
Zurück zum Zitat Moss SE, Klein R, Klein BE. The 14-year incidence of visual loss in a diabetic population. Ophthalmology. 1998;105:998–1003.PubMedCrossRef Moss SE, Klein R, Klein BE. The 14-year incidence of visual loss in a diabetic population. Ophthalmology. 1998;105:998–1003.PubMedCrossRef
3.
Zurück zum Zitat Moss SE, Klein R, Klein BE. The 10-year incidence of visual loss in a diabetic population. Ophthalmology. 1994;101:1061–70.PubMedCrossRef Moss SE, Klein R, Klein BE. The 10-year incidence of visual loss in a diabetic population. Ophthalmology. 1994;101:1061–70.PubMedCrossRef
4.
Zurück zum Zitat Wild S, Roglic G, Green A, et al. Global prevalence of diabetes: estimates for the year 2000 and projections for 2030. Diabetes Care. 2004;27:1047.PubMedCrossRef Wild S, Roglic G, Green A, et al. Global prevalence of diabetes: estimates for the year 2000 and projections for 2030. Diabetes Care. 2004;27:1047.PubMedCrossRef
5.
Zurück zum Zitat Early Treatment Diabetic Retinopathy Study Research Group. Photocoagulation for diabetic macular edema. Early Treatment Diabetic Retinopathy Study Report number 1. Arch Opthalmol. 1985;103:1796–806.CrossRef Early Treatment Diabetic Retinopathy Study Research Group. Photocoagulation for diabetic macular edema. Early Treatment Diabetic Retinopathy Study Report number 1. Arch Opthalmol. 1985;103:1796–806.CrossRef
6.
Zurück zum Zitat The Diabetic Retinopathy Clinical Research Network, Elan MJ, Aiello LP, Beck RW, et al. Randomized trail evaluating ranibizumab plus prompt or deferred laser or triamcinolone plus prompt laser for diabetic macular edema. Ophthalmology. 2010;117:1064–77.CrossRef The Diabetic Retinopathy Clinical Research Network, Elan MJ, Aiello LP, Beck RW, et al. Randomized trail evaluating ranibizumab plus prompt or deferred laser or triamcinolone plus prompt laser for diabetic macular edema. Ophthalmology. 2010;117:1064–77.CrossRef
7.
Zurück zum Zitat The Diabetic Retinopathy Clinical Research Network, Elan MJ, Bressler NM, Qin H, et al. Expanded 2-year follow-up of ranibizumab plus prompt or deferred laser or triamcinolone plus prompt laser for diabetic macular edema. Ophthalmology. 2011;118:609–14.CrossRef The Diabetic Retinopathy Clinical Research Network, Elan MJ, Bressler NM, Qin H, et al. Expanded 2-year follow-up of ranibizumab plus prompt or deferred laser or triamcinolone plus prompt laser for diabetic macular edema. Ophthalmology. 2011;118:609–14.CrossRef
8.
Zurück zum Zitat Nguyen QD, Shah SM, Khwaja AA, et al., READ-2 Study Group. Two-year outcome of ranibizumab for edema of the macula in diabetes (READ-2) study. Ophthalmology. 2010;117:2146–51.PubMedCrossRef Nguyen QD, Shah SM, Khwaja AA, et al., READ-2 Study Group. Two-year outcome of ranibizumab for edema of the macula in diabetes (READ-2) study. Ophthalmology. 2010;117:2146–51.PubMedCrossRef
9.
Zurück zum Zitat Nguyen QD, Shah SM, Khwaja AA, et al., READ-2 Study Group. Primary end point (six months) results of the ranibizumab for edema of the macula in diabetes (READ-2) study. Ophthalmology. 2009;116:2175–81.PubMedCrossRef Nguyen QD, Shah SM, Khwaja AA, et al., READ-2 Study Group. Primary end point (six months) results of the ranibizumab for edema of the macula in diabetes (READ-2) study. Ophthalmology. 2009;116:2175–81.PubMedCrossRef
10.
Zurück zum Zitat Mitchell P, Bandello F, Schmidt-Erfurth U, et al., RESTORE Study Group. The RESTORE study: ranibizumab monotherapy or combined with laser versus laser monotherapy for diabetic macular edema. Ophthalmology. 2011;118:615–25.PubMedCrossRef Mitchell P, Bandello F, Schmidt-Erfurth U, et al., RESTORE Study Group. The RESTORE study: ranibizumab monotherapy or combined with laser versus laser monotherapy for diabetic macular edema. Ophthalmology. 2011;118:615–25.PubMedCrossRef
11.
Zurück zum Zitat Massin P, Bandello F, Justus GG, et al. Safety and efficacy of ranibizumab in diabetic macular edema (RESOLVE study). Diabetes Care. 2010;33:2399–405.PubMedCrossRef Massin P, Bandello F, Justus GG, et al. Safety and efficacy of ranibizumab in diabetic macular edema (RESOLVE study). Diabetes Care. 2010;33:2399–405.PubMedCrossRef
12.
Zurück zum Zitat Nguyen QD, Brown DM, Marcus DM, et al. Ranibizumab for diabetic macular edema. Results from 2 phase III randomized trials: rise and ride. Ophthalmology. 2012;119:789–801.PubMedCrossRef Nguyen QD, Brown DM, Marcus DM, et al. Ranibizumab for diabetic macular edema. Results from 2 phase III randomized trials: rise and ride. Ophthalmology. 2012;119:789–801.PubMedCrossRef
13.
Zurück zum Zitat Michaelides M, Kaines A, Hamilton RD, et al. A prospective randomized trail of intravitreal bevacizumab or laser therapy in the management of diabetic macular edema (BOLT study) 12-month data: report 2. Ophthalmology. 2010;117:1078–86.PubMedCrossRef Michaelides M, Kaines A, Hamilton RD, et al. A prospective randomized trail of intravitreal bevacizumab or laser therapy in the management of diabetic macular edema (BOLT study) 12-month data: report 2. Ophthalmology. 2010;117:1078–86.PubMedCrossRef
14.
Zurück zum Zitat Rajendram R, Fraser-Bell S, Kaines A, et al. A 2-year prospective randomized controlled trial of intravitreal bevacizumab or laser therapy (BOLT) in the management of diabetic macular edema 24-month data: report 3. Arch Opthalmol. 2012;130:927–79.CrossRef Rajendram R, Fraser-Bell S, Kaines A, et al. A 2-year prospective randomized controlled trial of intravitreal bevacizumab or laser therapy (BOLT) in the management of diabetic macular edema 24-month data: report 3. Arch Opthalmol. 2012;130:927–79.CrossRef
15.
Zurück zum Zitat Comparison of Age-related Macular Degeneration Treatments Trials (CATT) Research Group, Martin DF, Maguire MG, Ying GS, et al. Ranibizumab and bevacizumab for neovascular age-related macular degeneration. N Engl J Med. 2011;364:1897–908.PubMedCrossRef Comparison of Age-related Macular Degeneration Treatments Trials (CATT) Research Group, Martin DF, Maguire MG, Ying GS, et al. Ranibizumab and bevacizumab for neovascular age-related macular degeneration. N Engl J Med. 2011;364:1897–908.PubMedCrossRef
16.
Zurück zum Zitat Comparison of Age-related Macular Degeneration Treatments Trials (CATT) Research Group, Martin DF, Maguire MG, Fine SL, et al. Ranibizumab and bevacizumab for treatment of neovascular age-related macular degeneration: two-year results. Ophthalmology. 2012;119:1388–98.PubMedCrossRef Comparison of Age-related Macular Degeneration Treatments Trials (CATT) Research Group, Martin DF, Maguire MG, Fine SL, et al. Ranibizumab and bevacizumab for treatment of neovascular age-related macular degeneration: two-year results. Ophthalmology. 2012;119:1388–98.PubMedCrossRef
Metadaten
Titel
The incidence and treatment of diabetic macular edema at the University Eye-Clinic Graz for a period of 2 years
verfasst von
Dr Monja Michelitsch
Priv-Doz Dr Vanessa Gasser-Steiner
Univ -Prof Dr phil Peter Gasser-Steiner
Publikationsdatum
01.10.2013
Verlag
Springer Vienna
Erschienen in
Spektrum der Augenheilkunde / Ausgabe 5/2013
Print ISSN: 0930-4282
Elektronische ISSN: 1613-7523
DOI
https://doi.org/10.1007/s00717-013-0185-2

Weitere Artikel der Ausgabe 5/2013

Spektrum der Augenheilkunde 5/2013 Zur Ausgabe

editorial

Editorial